Effect of Moxifloxacin Versus Gatifloxacin on Corneal Epithelium Following Pterygium Excision
Not Applicable
- Conditions
- Primary Pterygium
- Interventions
- Registration Number
- NCT00892918
- Lead Sponsor
- Meir Medical Center
- Brief Summary
The purpose of this study is to determine whether there is a difference in corneal epithelial healing rate and/or toxicity following pterygium excision, between eyes treated post-operatively by moxifloxacin(VIGAMOX)versus gatifloxacin (ZYMAR).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
- diagnosis of primary pterygium with a clinical indication for surgery
- informed consent
Exclusion Criteria
- known allergic reaction to fluoroquinolones.
- secondary\recurrent pterygium or clinical suspected conjunctival tumor.
- eye surgery in the last 6 months.
- eye disorders: severe dry eye syndrome, ocular surface diseases, glaucoma, recurrent corneal erosions, chronic corneal diseases, after chemical burn.
- low compliance.
- pregnancy
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Gatifloxacin Moxifloxacin ophthalmic solution 0.5% ; Gatifloxacin ophthalmic solution 0.3% About 20 patients treated by Gatifloxacin ophthalmic solution 0.3% (Zymar) 4 times a day (one drop each time) after pterygium excision with Mitomycin C application. Moxifloxacin Moxifloxacin ophthalmic solution 0.5% ; Gatifloxacin ophthalmic solution 0.3% About 20 patients treated by Moxifloxacin ophthalmic solution 0.5% (Vigamox) 4 times a day (one drop each time) after pterygium excision with Mitomycin C application.
- Primary Outcome Measures
Name Time Method rate of corneal epithelial defect closure 21 days
- Secondary Outcome Measures
Name Time Method toxicity findings: punctate keratitis, inferior conjunctival hyperemia, conjunctival papillary reaction 12 days
Trial Locations
- Locations (1)
Meir Medical Center
🇮🇱Kfar Saba, Israel